Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

PR-104

Known as: PR104 
A non-toxic, small-molecule, hypoxia-activated, 3,5-dinitrobenzamide nitrogen mustard pre-prodrug with potential antitumor activity. Upon intravenous… 
National Institutes of Health

Related topics

Related topics

2 relations
DNA

Broader (1)

Nitrogen Mustard Compounds

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Therapeutic journery of nitrogen mustard as alkylating anticancer agents: Historic to future perspectives.
Cancer is considered as one of the most serious health problems today. The discovery of nitrogen mustard as an alkylating agent… 
  • figure 8
  • figure 19
  • figure 2
  • figure 1
  • figure 2
2015
2015
Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma
PR-104 is a clinical stage bioreductive prodrug that is converted in vivo to its cognate alcohol, PR-104A. This dinitrobenzamide… 
Highly Cited
2015
Highly Cited
2015
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
We previously demonstrated vast expansion of hypoxic areas in the leukemic microenvironment and provided a rationale for using… 
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Review
2014
Review
2014
Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
Hypoxia, a state of low oxygen, is a common feature of solid tumors and is associated with disease progression as well as… 
  • figure 1
2013
2013
The Role of Bystander Effects in the Antitumor Activity of the Hypoxia-Activated Prodrug PR-104
Activation of prodrugs in tumors (e.g., by bioreduction in hypoxic zones) has the potential to generate active metabolites that… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2011
Highly Cited
2011
Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104
Recent studies indicate that interactions between leukemia cells and the bone marrow (BM) microenvironment promote leukemia cell… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2011
Highly Cited
2011
A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients
BackgroundThe phosphate ester PR-104 is rapidly converted in vivo to the alcohol PR-104A, a nitrogen mustard prodrug that is… 
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Review
2010
Review
2010
The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.
PR-104, currently in phase II clinical trials, is a phosphate ester pre-prodrug which is converted in vivo to its cognate alcohol… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2009
Highly Cited
2009
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors
PurposePR-104 is a “pre-prodrug” designed to be activated to a dinitrobenzamide nitrogen mustard cytotoxin by nitroreduction in… 
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Highly Cited
2007
Highly Cited
2007
Mechanism of Action and Preclinical Antitumor Activity of the Novel Hypoxia-Activated DNA Cross-Linking Agent PR-104
Purpose: Hypoxia is a characteristic of solid tumors and a potentially important therapeutic target. Here, we characterize the… 
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE